Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | The epidemiology and treatment of chronic GvHD post-alloSCT

Marcello Rotta • 11 Dec 2023
ASH 2023
General Antibodies Belumosudil Ibrutinib Rituximab Ruxolitinib

Marcello Rotta, MD, Colorado Blood Cancer Institute, Denver, CO, discusses the complex epidemiology and treatment of chronic graft-versus-host disease (GvHD) following allogeneic stem cell transplantation (alloSCT). GvHD manifests in diverse phenotypes and impacts multiple organs, making treatment complex. Dr Rotta discusses potential therapies, including standard immune suppression, monoclonal antibodies, and novel agents like ibrutinib and ruxolitinib. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Marcello Rotta

1:54
COVALENT-103: investigating BMF-500, an oral covalent FLT3 inhibitor, in acute leukemias
Marcello Rotta • 11 Dec 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals